A drug-eluting injectable nanogel for localized delivery of anticancer drugs to solid tumors

dc.contributor.authorGodau, Brent
dc.contributor.authorSamimi, Sadaf
dc.contributor.authorSeyfoori, Amir
dc.contributor.authorSamiei, Ehsan
dc.contributor.authorKhani, Tahereh
dc.contributor.authorNaserzadeh, Parvaneh
dc.contributor.authorNajafabadi, Alireza Hassani
dc.contributor.authorLesha, Emal
dc.contributor.authorMajidzadeh-A, Keivan
dc.contributor.authorAshtari, Behnaz
dc.contributor.authorCharest, Gabriel
dc.contributor.authorMorin, Christophe
dc.contributor.authorFortin, David
dc.contributor.authorAkbari, Mohsen
dc.date.accessioned2024-01-24T23:07:26Z
dc.date.available2024-01-24T23:07:26Z
dc.date.copyright2023en_US
dc.date.issued2023
dc.description.abstractSystemically administered chemotherapy reduces the efficiency of the anticancer agent at the target tumor tissue and results in distributed drug to non-target organs, inducing negative side effects commonly associated with chemotherapy and necessitating repeated administration. Injectable hydrogels present themselves as a potential platform for non-invasive local delivery vehicles that can serve as a slow-releasing drug depot that fills tumor vasculature, tissue, or resection cavities. Herein, we have systematically formulated and tested an injectable shear-thinning hydrogel (STH) with a highly manipulable release profile for delivering doxorubicin, a common chemotherapeutic. By detailed characterization of the STH physical properties and degradation and release dynamics, we selected top candidates for testing in cancer models of increasing biomimicry. Two-dimensional cell culture, tumor-on-a-chip, and small animal models were used to demonstrate the high anticancer potential and reduced systemic toxicity of the STH that exhibits long-term (up to 80 days) doxorubicin release profiles for treatment of breast cancer and glioblastoma. The drug-loaded STH injected into tumor tissue was shown to increase overall survival in breast tumor- and glioblastoma-bearing animal models by 50% for 22 days and 25% for 52 days, respectively, showing high potential for localized, less frequent treatment of oncologic disease with reduced dosage requirements.en_US
dc.description.reviewstatusRevieweden_US
dc.description.scholarlevelFacultyen_US
dc.description.sponsorshipWe would like to acknowledge funds received from Natural Sciences and Engineering Research Council of Canada (NSERC), BC Cancer Foundation, Cancer Research Society, Canada Foundation for Innovation, and the B.C. Knowledge Development Fund.en_US
dc.identifier.citationGodau, B., Samimi, S., Seyfoori, A., Samiei, E., Khani, T., Naserzadeh, P., Najafabadi, A. H., Lesha, E., Majidzadeh-A, K., Ashtari, B., Charest, G., Morin, C., Fortin, D., & Akbari, M. (2023). A drug-eluting injectable nanogel for localized delivery of anticancer drugs to solid tumors. Pharmaceutics, 15(9), 2255. https://doi.org/10.3390/pharmaceutics15092255en_US
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics15092255
dc.identifier.urihttp://hdl.handle.net/1828/15871
dc.language.isoenen_US
dc.publisherPharmaceuticsen_US
dc.subjectlocalized therapyen_US
dc.subjectshear-thinning hydrogelen_US
dc.subjectcancer therapyen_US
dc.subjectglioblastomaen_US
dc.subjectbreast canceren_US
dc.titleA drug-eluting injectable nanogel for localized delivery of anticancer drugs to solid tumorsen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
godau_brent_pharmaceutics_2023.pdf
Size:
2.76 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2 KB
Format:
Item-specific license agreed upon to submission
Description: